|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00341926 |
Purpose
RATIONALE: Gathering information about risk factors for lung cancer and exposure to smoky coal and other types of fuel in non-smoking women in China may help the study of lung cancer in the future.
PURPOSE: This clinical trial is studying genetic risk factors for lung cancer in non-smoking women in Xuan Wei and Fu Yuan Counties in Yun Nan Province, China.
| Condition | Intervention |
|---|---|
|
Lung Cancer |
Procedure: evaluation of cancer risk factors Procedure: laboratory biomarker analysis Procedure: molecular genetic technique Procedure: study of high risk factors |
| Study Type: | Observational |
| Official Title: | A Hospital-Based Case-Control Study of Non-Smoking Women in Xuan Wei and Fu Yuan, China |
| Estimated Enrollment: | 1150 |
| Study Start Date: | February 2006 |
OBJECTIVES:
OUTLINE: Patients wear small badges designed to measure the amount of particulate matter and other chemicals they are exposed to and a small patch sampler on the wrist, neck, and shoulder to measure the amount of smoky coal exposure to the skin.
Patients undergo collection of blood and urine samples over 2 days, buccal cells on 1 day, and sputum samples over 5 days. Samples are analyzed by assays to test the ability to repair PAH-damaged DNA and apoptotic capacity and to measure integrative markers of genomic stability such as telomere length and oxidative damage in mitochondrial DNA.
Eligibility| Ages Eligible for Study: | 18 Years to 79 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
Newly diagnosed primary lung cancer and meets 1 of the following criteria:
No lung cancer and meets 1 of the following criteria:
PATIENT CHARACTERISTICS:
No patients with any of the following conditions:
PRIOR CONCURRENT THERAPY:
Contacts and Locations| United States, Maryland | |
| Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Recruiting |
| Bethesda, Maryland, United States, 20892-1182 | |
| Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937 | |
| China | |
| China National Environmental Monitoring Center | Recruiting |
| Beijing, China, 100029 | |
| Contact: Contact Person 86-10-6711-3786 | |
| Principal Investigator: | Qing Lan, MD | National Cancer Institute (NCI) |
| Principal Investigator: | Nathaniel Rothman, MD | National Cancer Institute (NCI) |
| Principal Investigator: | Min Shen, MD, PhD | National Cancer Institute (NCI) |
More Information
| Study ID Numbers: | CDR0000553203, NCI-06-C-N092, 999906092, CNEMC-IRB00001957 |
| Study First Received: | June 19, 2006 |
| Last Updated: | December 11, 2008 |
| ClinicalTrials.gov Identifier: | NCT00341926 |
| Health Authority: | Unspecified |
|
small cell lung cancer non-small cell lung cancer stage I non-small cell lung cancer stage II non-small cell lung cancer stage III non-small cell lung cancer |
stage IIIA non-small cell lung cancer stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer extensive stage small cell lung cancer limited stage small cell lung cancer |
|
Thoracic Neoplasms Carcinoma, Small Cell Non-small cell lung cancer Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung |
|
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site |
